Search for a trial

Long-Term, Open-Label, Safety Study of LY2216684 12 to 18 mg Once Daily as Adjunctive Treatment for Patients with Major Depressive Disorder Who are Partial Responders to Selective Serotonin Reuptake Inhibitor Treatment

The primary objective of this study is to evaluate the long-term safety and tolerability of LY2216684 administered once daily (QD) in the adjunctive treatment with a selective serotonin reuptake inhibitor (SSRI) for up to approximately 1 year in…

STRENGTHS: Fostering responsive mental health systems in the Syrian refugee crisis

Primary Objective:To evaluate feasibility, acceptability, effectiveness and cost-effectiveness of the culturally adapted PM+ intervention forSyrian refugees in The Netherlands.Secondary Objective(s):1. To translate and (culturally) adapt PM+ for use…